2D and 3D Cellular Screening Models and AI Guided Analysis
- 1st Edition, Volume 204 - April 1, 2026
- Latest edition
- Editors: Oliver Kepp, Lorenzo Galluzzi, Guido Kroemer
- Language: English
This book provides a comprehensive overview of the latest advancements in cellular screening models, with a particular focus on both 2D and 3D systems. It explores the development,… Read more
This book provides a comprehensive overview of the latest advancements in cellular screening models, with a particular focus on both 2D and 3D systems. It explores the development, application, and comparative benefits of 2D monolayer cultures and 3D organoids, spheroids, and tissue-engineered constructs for biomedical research and drug discovery.
- Detailed methodologies and protocols for developing both 2D monolayer and 3D spheroid/organoid cellular screening models.
- In-depth comparison of advantages, limitations, and applications of 2D vs. 3D cellular models in research and drug discovery.
- Description of high-throughput and high-content screening methods for assessing cellular responses
Academic researchers, Professionals, Graduate students
1. Preface
Guido Kroemer and Oliver Kepp
2. High throughput CellTiter-glo viability assessment
Dana Alawieh and Aline Renneville
3. Assessing viability of cancer cell spheroids in 3D drug screening
Oliver Kepp and Marion Leduc
4. 3D killing assay of cancer spheroids by cytotoxic T lymphocytes in anchored microfluidic droplets
Charles Baroud
5. Use of micropatterning for 3D cell culture
Emna Ouni and Kristine Schauer
6. Use of microfluidic chip devices for assessing the effect of radiation on 3D cell culture models
Philip Wong, Rodin Chermat, Elena Refet-Mollof, Maryam Ziaee, Julie Lafontaine and Thomas Gervais
7. A 3D model for assessing regulated cell death modalities
Dmitri Krysko and Robin Demuynck
8. YOLO detection model for Cell Viability assessment
Felix Peyre
9. Bioinformatics and AI/ML approaches using multi-omics data to accelerate diagnosis and delivery of precision care
Zeeshan Ahmed, Kritika Singh, Sarah Usman, Saman Zeeshan, Naveena Yanamala, Vikram Bhise, Mark Nichols, Sabahat Bokhari and Partho Sengupta
10. Automated image analysis and machine learning for the assessment of mitochondrial membrane potential
Marta Giacomello, Camilla Bean, Federica Dal bello, Emad Norouzi Esfahani, Alessio Gianelle, Saradha Ramesh, Luca Persano, Elena Rampazzo and Caterina Vianello
11. Assessing cancer cell heterogeneity in patient-derived tumoroids
Flora Doffe
12. Assessment of lysosomal drug sequestration and release using fluorescence microscopy
Karla Alvarez, Mojgan Djavaheri-Mergny, Guido Kroemer, Lucille Ferret, Samy Dehissi and Jean Guillon
13. Assessment of T cell toxicity in ex-vivo models of cancer
Emmanuel intégrative des tumeurs et immunothérapie Donnadieu and Alice Machado
14. Three-dimensional Organoid Screening using Leica Thunder Microscope
Manoliu Tudor
15. Using vascularized organoids-on-chip for assessing systemic drug delivery
Xavier Gidrol, Emily Tubbs, Fabrice P Navarro and Yves Fouillet
16. Quantitative assessment of nanoparticle uptake and trafficking in 3D cell culture models
Meritxell B. Cutrona
17. Fluorescence microscopic quantitation of lysosomal cholesterol accumulation induced by cationic amphiphilic drugs
Mojgan Djavaheri-Mergny, Karla Alvarez, Samy Dehissi, Lucille Ferret and Guido Kroemer
Guido Kroemer and Oliver Kepp
2. High throughput CellTiter-glo viability assessment
Dana Alawieh and Aline Renneville
3. Assessing viability of cancer cell spheroids in 3D drug screening
Oliver Kepp and Marion Leduc
4. 3D killing assay of cancer spheroids by cytotoxic T lymphocytes in anchored microfluidic droplets
Charles Baroud
5. Use of micropatterning for 3D cell culture
Emna Ouni and Kristine Schauer
6. Use of microfluidic chip devices for assessing the effect of radiation on 3D cell culture models
Philip Wong, Rodin Chermat, Elena Refet-Mollof, Maryam Ziaee, Julie Lafontaine and Thomas Gervais
7. A 3D model for assessing regulated cell death modalities
Dmitri Krysko and Robin Demuynck
8. YOLO detection model for Cell Viability assessment
Felix Peyre
9. Bioinformatics and AI/ML approaches using multi-omics data to accelerate diagnosis and delivery of precision care
Zeeshan Ahmed, Kritika Singh, Sarah Usman, Saman Zeeshan, Naveena Yanamala, Vikram Bhise, Mark Nichols, Sabahat Bokhari and Partho Sengupta
10. Automated image analysis and machine learning for the assessment of mitochondrial membrane potential
Marta Giacomello, Camilla Bean, Federica Dal bello, Emad Norouzi Esfahani, Alessio Gianelle, Saradha Ramesh, Luca Persano, Elena Rampazzo and Caterina Vianello
11. Assessing cancer cell heterogeneity in patient-derived tumoroids
Flora Doffe
12. Assessment of lysosomal drug sequestration and release using fluorescence microscopy
Karla Alvarez, Mojgan Djavaheri-Mergny, Guido Kroemer, Lucille Ferret, Samy Dehissi and Jean Guillon
13. Assessment of T cell toxicity in ex-vivo models of cancer
Emmanuel intégrative des tumeurs et immunothérapie Donnadieu and Alice Machado
14. Three-dimensional Organoid Screening using Leica Thunder Microscope
Manoliu Tudor
15. Using vascularized organoids-on-chip for assessing systemic drug delivery
Xavier Gidrol, Emily Tubbs, Fabrice P Navarro and Yves Fouillet
16. Quantitative assessment of nanoparticle uptake and trafficking in 3D cell culture models
Meritxell B. Cutrona
17. Fluorescence microscopic quantitation of lysosomal cholesterol accumulation induced by cationic amphiphilic drugs
Mojgan Djavaheri-Mergny, Karla Alvarez, Samy Dehissi, Lucille Ferret and Guido Kroemer
- Edition: 1
- Latest edition
- Volume: 204
- Published: April 1, 2026
- Language: English
OK
Oliver Kepp
Dr. Oliver Kepp graduated from Humboldt University Berlin and obtained a PhD degree in Molecular Biology. Today he is a tenured researcher at INSERM and a Co-director of the BioCell automation platform at GRCC. Oliver and his team investigate several aspects of tumor immunogenicity, focusing on systems cell biology approaches. He is also a co-founder of Samsara therapeutics and was appointed associate director of the European academy of tumor immunology in 2019. Oliver received the prestigious Clarivate Highly Cited Researcher Award four years in a row since 2018 and has recently been ranked among the top biology and biochemistry scientists in France (#5; www.research.com)
Affiliations and expertise
Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, FranceLG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USAGK
Guido Kroemer
Guido Kroemer got his M.D. in 1985 from the University of Innsbruck, Austria, and his Ph.D. in molecular biology in 1992 from the Autonomous University of Madrid, Spain. He is currently Professor at the Faculty of Medicine of the University of Paris Descartes/Paris V, Director of the INSERM research team ‘Apoptosis, Cancer and Immunity’, Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Cancer Campus, and Practitioner at the Hôpital Européen George Pompidou (Paris, France). He is also the Director of the Paris Alliance of Cancer Research Institutes (PACRI) and the Labex 'Immuno-Oncology'. Dr. Kroemer is best known for the discoveries that mitochondrial membrane permeabilization constitutes a decisive step in regulated cell death; that autophagy is a cytoprotective mechanism with lifespan-extending effects; and that anticancer therapies are successful only if they stimulate tumour-targeting immune responses. He is currently the most-cited cell biologist in Europe (relative to the period 2007-2013), and he has received the Descartes Prize of the European Union, the Carus Medal of the Leopoldina, the Dautrebande Prize of the Belgian Royal Academy of Medicine, the Léopold Griffuel Prize of the French Association for Cancer Research, the Mitjavile prize of the French National Academy of Medicine and a European Research Council Advanced Investigator Award.
Affiliations and expertise
INSERM Cordeliers Research Cancer Paris; Hopital Europeen Georges Pompidou; Universite Paris Descartes, France